April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Rescue of Complement Mediated Pathology in a Murine Model of Macular Degeneration by Adenovirus-Mediated Delivery of the Alternative Pathway Regulator, Factor H
Author Affiliations & Notes
  • Rajendra Kumar-Singh
    Ophthalmology, Tufts University School of Medicine, Boston, MA
  • Siobhan M Cashman
    Ophthalmology, Tufts University School of Medicine, Boston, MA
  • Footnotes
    Commercial Relationships Rajendra Kumar-Singh, None; Siobhan Cashman, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1319. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rajendra Kumar-Singh, Siobhan M Cashman; Rescue of Complement Mediated Pathology in a Murine Model of Macular Degeneration by Adenovirus-Mediated Delivery of the Alternative Pathway Regulator, Factor H. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1319.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have previously described a murine model of complement activation in the retina that recapitulates many of the features of age-related macular degeneration (AMD), including increased vascular permeability, endothelial cell proliferation, RPE cell atrophy and photoreceptor degeneration. This model manifests these features within 2 weeks of injection of an adenovirus expressing murine complement component 3 (AdcmvC3). In this study, we investigated the potential of factor H, a complement regulator strongly implicated in AMD, to attenuate the AdcmvC3-induced phenotype by co-injection of an adenovirus expressing factor H.

Methods: We constructed an adenovirus expressing murine factor H (AdCAGfH). Adult mice were co-injected with either AdcmvC3 and AdCAGfH or AdcmvC3 and and a control virus, AdcmvGFP, into the subretinal space. At 8 days post-injection, mice were analyzed by electroretinography. Eyes were harvested for analysis by histology and immunohistochemistry.

Results: Mice co-injected with AdcmvC3 and AdCAGfH showed a 110% and 140% increase in A- and B-waves, respectively, relative to mice co-injected with AdcmvC3 and AdcmvGFP. While rescue of RPE cell phenotype was not complete, with persistent hypertrophy and hyperplasia observed in eyes injected with AdcmvC3 and AdCAGfH, a significant 125% reduction in RPE cell atrophy was observed relative to control eyes. While complete loss of outer segments occurred in >50% of the lesion in control eyes, <10% of the lesion in eyes co-injected with AdcmvC3 and AdCAGfH had complete outer segment loss. Staining for endothelial cells, using Griffonia Simplificolia Lectin I (GSL I), indicated a 275% reduction in GSL I staining in eyes injected with AdcmvC3 and AdCAGfH relative to control-injected eyes.

Conclusions: The AdcmvC3-induced features of a murine model of complement activation in the retina can be attenuated by adenovirus-mediated delivery of the alternative complement pathway regulator, factor H. This model will be useful in investigating the potential of other anti-complement therapies for treatment of AMD and other complement-mediated diseases of the retina.

Keywords: 412 age-related macular degeneration • 538 gene transfer/gene therapy • 637 pathology: experimental  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×